

The Push to Detect Cancer Earlier: Cell-Free DNA (cfDNA) Blood Tests in Primary Care

Resource	Address
Ahlquist DA. Universal cancer screening: revolutionary, rational, and realizable. <i>NPJ Precis Oncol.</i> 2018;2:23.	https://pubmed.ncbi.nlm.nih.gov/30393772/
Aravanis AM, Lee M, Klausner RD. Next-generation sequencing of circulating tumor DNA for early cancer detection. <i>Cell.</i> 2017;168(4):571-574.	https://pubmed.ncbi.nlm.nih.gov/28187279/
Aravanis AM, Oxnard GR, Maddala T, et al. Development of plasma cell-free DNA (cfDNA) assays for early cancer detection: first insights from the Circulating Cell-Free Genome Atlas Study (CCGA). <i>AACR.</i> 2018; 78(13):Supplement LB-343.	https://pubmed.ncbi.nlm.nih.gov/28187279/
Arora NS, Davis JK, Kirby C, et al. Communication challenges for nongeneticist physicians relaying clinical genomic results. <i>Per Med.</i> 2016;14(5):423-431.	https://pubmed.ncbi.nlm.nih.gov/29181085/
Barefoot M, Loyfer N, Kiliti A, et al. Detection of Cell Types Contributing to Cancer From Circulating, Cell-Free Methylated DNA. <i>Front Genet.</i> 2021;12:671057.	https://pubmed.ncbi.nlm.nih.gov/34386036/
Cho H, Mariotto AB, Schwartz LM, et al. When do changes in cancer survival mean progress? The insight from population incidence and mortality. <i>J Natl Cancer Inst Monogr.</i> 2014;2014(49):187-197.	https://pubmed.ncbi.nlm.nih.gov/25417232/
Christensen KD, Vassy JL, Jamal L, et al. Are physicians prepared for whole genome sequencing? A qualitative analysis. <i>Clin Genet.</i> 2016;89(2):228-234.	https://pubmed.ncbi.nlm.nih.gov/26080898/
ClinicalTrials.gov. Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice.	https://clinicaltrials.gov/ct2/show/NCT04241796

ClinicalTrials.gov. The Circulating Cell-free Genome Atlas Study (CCGA).	https://clinicaltrials.gov/ct2/show/NCT02889978
ClinicalTrials.gov. Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing (ASCEND).	https://clinicaltrials.gov/ct2/show/NCT04213326
ClinicalTrials.gov. Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode (ECLIPSE).	https://clinicaltrials.gov/ct2/show/NCT04136002
ClinicalTrials.gov. The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types.	https://clinicaltrials.gov/ct2/history/NCT03085888
ClinicalTrials.gov. The SUMMIT Study: A Cancer Screening Study (SUMMIT).	https://www.clinicaltrials.gov/ct2/show/NCT03934866
Lawler M, Alsina D, Adams RA, et al. Critical research gaps and recommendations to inform research prioritization for more effective prevention and improved outcomes in colorectal cancer. <i>Gut</i> . 2018;67(1):179-193.	https://pubmed.ncbi.nlm.nih.gov/29233930/
Melton C, Freese P, Bagaria S, et al. Optimized early cancer detection from whole genome sequencing of cell-free DNA. Presented at the 2019 Annual Meeting of The American Society of Human Genetics, Houston, TX.	https://www.ashg.org/wp-content/uploads/2019/10/ASHG-2019-poster-abstracts.pdf
Oxnard GR, Klein EA, Seiden M, et al. Simultaneous multi-cancer detection and tissue of origin (TOO) localization using targeted bisulfite sequencing of plasma cell-free DNA (cfDNA). <i>J Glob Oncol</i> . 2019; 5 (suppl):44-44.	https://ascopubs.org/doi/abs/10.1200/JGO.2019.5.suppl.44
Ranucci R. Cell-Free DNA: Applications in Different Diseases. <i>Methods Mol Biol</i> . 2019;1909:3-23.	https://pubmed.ncbi.nlm.nih.gov/30580419/
Razavi P, Li BT, Brown DN, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. <i>Nat Med</i> . 2019;25(12):1928-1937.	https://pubmed.ncbi.nlm.nih.gov/31768066/

Salvi S, Gurioli G, De Giorgi U, et al. Cell-free DNA as a diagnostic marker for cancer: current insights. <i>Onco Targets Ther.</i> 2016;9:6549-6559.	https://doi.org/10.2147/OTT.S100901
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2021. <i>CA Cancer J Clin.</i> 2021;71:7-33.	https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21654
Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. <i>CA Cancer J Clin.</i> 2019;69(3):184-210.	https://pubmed.ncbi.nlm.nih.gov/30875085/
Stroun M, Maurice P, Vasioukhin V, et al. The origin and mechanism of circulating DNA. <i>Ann N Y Acad Sci.</i> 2000;906:161-168.	https://pubmed.ncbi.nlm.nih.gov/10818614/
Ulrich BC, Paweletz CP. Cell-free DNA in oncology: gearing up for clinic. <i>Ann Lab Med.</i> 2018;38(1):1-8.	https://pubmed.ncbi.nlm.nih.gov/29071812/
Wolpin BM, Richards DA, Cohn AL, et al. Performance of a blood-based test for the detection of multiple cancer types. <i>J Clin Oncol.</i> 2020; 38(4_suppl):283-283.	https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.4_suppl.283
Yan, Y, Guo Q, Wang F, et al. Cell-Free DNA: Hope and Potential Application in Cancer. <i>Front Cell Dev Biol.</i> 2021;9:639233.	https://pubmed.ncbi.nlm.nih.gov/33693004/

Resources and Societies

Resource	Address
American Association for Cancer Research	https://www.aacr.org/
American Cancer Society	https://www.cancer.org/
American Society of Clinical Oncology	https://www.asco.org/
National Cancer Institute	https://www.cancer.gov/
National Comprehensive Cancer Network - Guidelines	https://www.nccn.org/professionals/physician_gls/default.aspx